1. Current Molecular and Clinical Landscape of ATRT – The Link to Future Therapies
- Author
-
Gastberger K, Fincke VE, Mucha M, Siebert R, Hasselblatt M, and Frühwald MC
- Subjects
swi/snf related matrix associated ,actin dependent regulator of chromatin ,subfamily b ,member 1 ,smarcb1 ,atypical teratoid rhabdoid tumor ,atrt ,central nervous system ,cns ,treatment ,pediatric ,cell cycle ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Katharina Gastberger,1,2 Victoria E Fincke,1,2 Marlena Mucha,1,2 Reiner Siebert,3 Martin Hasselblatt,4 Michael C Frühwald1,2 1Pediatrics and Adolescent Medicine, Swabian Children’s Cancer Center, University Medical Center Augsburg, Augsburg, Germany; 2Bavarian Cancer Research Center (BZKF), Augsburg, Germany; 3Institute of Human Genetics, Ulm University & Ulm University Medical Center, Ulm, Germany; 4Institute of Neuropathology, University Hospital Münster, Münster, GermanyCorrespondence: Michael C Frühwald, EU-RHAB Center, Swabian Children’s Cancer Center, Pediatrics and Adolescent Medicine, University Medical Center Augsburg, and Bavarian Cancer Research Center (BZKF), Stenglinstr. 2, Augsburg, 86156, Germany, Tel +49 821 400 9340, Fax +49 821 400 179201, Email michael.fruehwald@uk-augsburg.deAbstract: ATRT is a highly aggressive and rare pediatric CNS tumor of very young children. Its genetic hallmark is bi-allelic inactivation of SMARCB1 encoding INI1. Rarely SMARCA4 encoding BRG1 is affected. Up to 30% are associated with constitutional heterozygous pathogenic variants in one of the two genes, giving rise to the Rhabdoid-Tumor-Predisposition-Syndromes (RTPS) 1 and 2. Characteristic DNA methylation profiles distinguish ATRT from other SMARCB1-deficient entities. Three distinct subtypes ATRT-MYC, -TYR, and -SHH are on record. ATRT-SHH may be further divided into the subgroups ATRT-SHH1A, -SHH1B, and -SHH2. The cure of ATRT remains challenging, notwithstanding an increasing understanding of molecular pathomechanisms and genetic background. The implementation of multimodal institutional treatment protocols has improved prognosis. Regardless of treatment approaches, clinical risk factors such as age, metastases, and DNA methylation subtype affect survival probability. We provide a critical appraisal of current conventional multimodal regimens and emerging targeted treatment approaches investigated in clinical trials and entity-specific registries. Intense treatment approaches featuring radiotherapy (RT) and high-dose chemotherapy (HDCT) face the difficulty of balancing tumor control and treatment-related toxicity. Current approaches focus on minimizing radiation fields by proton beam therapy or to withhold RT in HDCT-only approaches. Still, a 40– 75% relapse rate upon first-line treatment reveals the need for novel treatment strategies in primary and even more in recurrent/refractory (r/r) disease. Among targeted treatments, immune checkpoint inhibitors and epigenetically active agents appear most promising. Success remains limited in single agent approaches. We hypothesize that mechanism-informed combination therapy will enhance response, as the low mutational burden of ATRT may contribute to acquiring resistance to single targeted agents. As DNA methylation group-specific gene expression profiles appear to influence response to distinct agents, the future treatment of ATRT should respect clinical and biological heterogeneity in risk group adjusted treatment protocols.Keywords: SWI/SNF related matrix associated, actin dependent regulator of chromatin, subfamily b, member 1, SMARCB1, atypical teratoid rhabdoid tumor, ATRT, central nervous system, CNS, treatment, pediatric, cell cycle
- Published
- 2023